|
|
|
View this email in your browser
|
|
|
|
|
|
|
|
|
|
Dear
Welcome to the latest research seeking participants, based on our search of the ANZ CTR.
Also, a quick reminder there are just 3 weeks left to enter the Australian Consumer Partnerships in Research 2025 Awards, which close for entries 22 April. If you have participated in research and had a great experience, nominate the team and what they did to make it great, so other researchers can learn from it. If you're a research centre that aims to provide participants with great research experiences, and have the data to show what you are doing is making a difference for participants, then nominate what
you do that's special or innovative. Finally, if you are a part of a partnership involving research professionals and health consumers aiming to improve research or the research sector, then nominate that work. Check out our recent Q&A webinar, if you'd like to know more about the Awards.
We are grateful to Bellberry, Save Our Sons Duchenne Foundation and Curtin University's enAble Institute for their financial
support of the Awards, as well all the in-kind supporters helping us promote the Awards. If your organisation wants to demonstrate its commitment to the consumer voice in research, please jump on board as a sponsor. We could really use the help.
Please reach out to me at any time you have questions or feedback about this newsletter or our work.
|
|
|
|
|
Last month the ANZCTR was out of action when we did our search. So to make sure we didn't miss anything, the following is a list of studies on the ANZCTR as at 31Mar starting between 1 Feb and 31 Mar 2025.
For more details, click on the links to access the specific trial information.Cancer - A Phase 2 Study of Olutasidenib with Temozolomide As Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed with High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations. NSW, QLD, WA.
- A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies. VIC.
- Locally Optimised Contouring With AI Technology for Radiotherapy (for adults planned for primary breast malignancy). NSW.
- Phase 1/2 Clinical Trial of S227928, as a Single Agent and in Combination With Venetoclax in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML). VIC, NSW.
- A Study to Compare BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma. NSW, QLD, SA, VIC, WA.
- A Study to Evaluate BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors. NSW, QLD.
- A Study to Compare BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer. NSW, VIC, QLD, WA.
- A Phase 1 Study of ARC101 in Advanced Solid Tumors. SA, VIC. Phase 1b Study of ORIC-114 in Combination with Amivantamab in Patients with EGFR Exon20 Insertion Mutant non-small cell lung carcinoma. VIC.
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors. NSW.
- Phase 0/1 Study of 177Lu-RAD202, a Lutetium-177 Radiolabeled Single
Domain Antibody Against Human Epidermal Growth Factor Receptor 2 in Patients with Advanced Solid Tumours. WA.
- A Clinical Study of V940 and BCG in People With Bladder Cancer. NSW.
- Radiation Therapy of the prostate, assessing toxicities and quality of life in patients with intermediate risk prostate cancer. VIC.
- A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer. VIC.
AutoImmunity, Infections + Vaccines Urology Respiratory Heart Related Musculoskeletal - DREAM: a trial of duloxetine compared to placebo for reducing leg pain in people with
chronic sciatica. ACT, NSW, NT, QLD, SA, TAS, WA, VIC.
- A Study to Evaluate JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis. NSW.
- The effect of a topical curcumin formulation (VAS101) on knee pain in adults with knee osteoarthritis. WA.
Neurological Dermatology Mental Health - Evaluating the use of digitally enhanced treatment models in early intervention for youth with bipolar disorder. VIC.
- The Effects of Insomnia Treatment on Overnight Regulation of Emotional Memories and Risk for Mental Disorders. NSW.
Intensive Care Pregnancy/Infant/Paediatric/Adolescent Obesity Healthy volunteers - Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Patients. SA.
- A Phase 1, First in Human Study of GB-7624 administered subcutaneously in Healthy Adult
participants. QLD.
- A Phase I, First in Human Study to Assess NYR-BI03 in Healthy Participants, When Administered as a 3-hour Infusion. NSW.
Other
|
|
|
Note we have no connection/involvement with any of the above studies. We source this list manually from multiple sources. Unless otherwise
indicated, we have not being paid to list the study, and a study appearing in this list is not an endorsement of the quality, relevance of or consumer involvement in the project. We encourage people to do their due dligence on the suitability of any research study for their specific circumstances.
If you are a sponsor or researcher that wants to let people know about your newly opened study, please complete our request form or contact us (it's free to list a study once).
|
|
|
|
- National public consultations on the Draft Quality Standards and Accreditation Scheme for Human Research Ethics Committees (HRECs)
We mentioned this consultation in our March newsletter, so this is just a reminder that you have until thr 17th Apr to submit feedback on the Draft Quality Standards for HRECs and the organisations that host them, as well as options for a proposed accreditation scheme. Learn more at this link or contact: ClinicalTrialsPolicy@health.gov.au
|
|
|
|
You have until the 22 April to submit a nomination for one of the six categories of Australian Consumer Partnerships in Research 2025 Awards (#CPIR2025Awards) below:
A. Excellence in Consumer Partnership in Non-Commercial Research
B. Excellence in Consumer Partnership in Industry-Funded Research and Development
C. Excellence in Consumer Partner Capacity Building
D. Excellence in Research Participant Experience
E. Outstanding individual consumer impact on Health and Medical Research
F. Outstanding Consumer Advisory Group Impact on Health and Medical Research
|
|
|
|
Do you have something to share in this newsletter? Submit a request to share it via the CCReW submission form.
|
|
|
|
Shop Now! Your purchase will help fund CCReW support activities like this newsletter, our 1800 Trials Helpline, CCReW travel scholarships, clinical trial participant thank you's & more. Visit the
shop.
|
|
|
|
|
|
|
|
You are receiving this email because you subscribed to this newsletter or the AccessCR database. Unsubscribe
|
|
|
|
|
|
|
AccessCR Pty Ltd
Ground floor
465 Victoria Avenue
Chatswood NSW 2067
Australia
|
|
|
|
|
|
|